1D~Alessio DA, Sandoval DA, Seeley RJ. New ways in which GLP-1 can regulate glucose homeostasis[J]. J Clin Invest, 2005, 115(12): 3 406-3 408.
2Nagell CF, Wettergren A, Orskov C, et al. Inhibitory effect of GLP- 1 on gastric motility persists after vagal deafferentation in pigs[J]. Stand J Gastroenterol, 2006,41(6) :667-672.
3Nakade Y, Tsukamoto K, Pappas TN, et al. Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats[J]. Brain Res,2006, 1111(1):117-121.
4Pannacciulli N, Le DS, Salbe AD, et al. Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans[J].Neuroimage,2007, 35(2):511-517.
5Osaka T, Endo M, Yamakawa M, etal. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system[J]. Peptides,2005, 26(9):1 623-1 631.
6Simonsen L, Holst JJ, Deacon CE Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs[J]. Diabetologia,2006, 49(4) :706-712.
7Hinnen D, Nielsen LL, Waninger A, et al. Incretin Mimetics and DPP-IV Inhibitors: New paradigms for the treatment of type 2 diabete[J]. J Am Board Faro Med,2006,19(6):612-620.
8Vilsboll T, Zdravkovie M, Le-Thi T, et al. Liraglutide, a long-acting human glueagon-like peptide-1 analog, given as monotherapy significantly improves glyeemie control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes[J]. Diabetes Care, 2007,30(6) :1 608-1 610.
9Nauck MA, Hompesch M, Filipczak R, et al. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemie control and lowers body weight in subjects with type 2 diabetes[J]. Exp Clin Endocrinol Diabetes,2006, 114(8) :417-423.
10Matikainen N, Manttari S, Schweizer A, etal. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes[J]. Diabetologia,2006 , 49(9) :2 049-2 057.
